www.dailywire.com By Tim Pearce
Drugmaker Bristol Myers Squibb is set to release a new schizophrenia treatment in the United Kingdom for the same price it’s listed for in the United States, a decision that will certainly please those in the White House who have fought to get Americans the same prices offered overseas.
The announcement, made by Bristol on Monday, follows a push from President Donald Trump for U.S. drugmakers to lower prescription drugs for Americans to the greatest extent possible. Bristol’s approach to the United Kingdom market aligns with the White House’s strategy to secure lower drug prices in the United States.
The pharmaceutical company has never before brought its price for a drug to parity across the United States and the United Kingdom. Adam Lenkowsky, chief commercialization officer at Bristol, said that the drug company is prepared to pull its drug, Cobenfy, from the European nation’s market if the relevant government authorities do not agree to the price listed in the United States, at $1,850 a month.
“Our intention is to work with NICE and NHS to make this medicine available, but we are prepared to make the difficult decision to walk away if they cannot better recognize the value our medicine brings to patients and society,” Lenkowsky said in a statement.
“We agree with the Trump Administration that other countries need to pay their fair share,” he added…
READ FULL ARTICLE HERE… (dailywire.com)
Home | Caravan to Midnight (zutalk.com)
Be First to Comment